COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda

FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.